The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts.
about
Zoledronic acid effectiveness against breast cancer metastases - a role for estrogen in the microenvironment?The ARF tumor suppressor regulates bone remodeling and osteosarcoma development in mice.How do bisphosphonates inhibit bone metastasis in vivo?Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasisUpdates on osteonecrosis of the jawZoledronate inhibits ischemia-induced neovascularization by impairing the mobilization and function of endothelial progenitor cellsIntegrins and bone metastasis: integrating tumor cell and stromal cell interactions.Anti-tumour activity of bisphosphonates in preclinical models of breast cancer.Effect of zoledronate on oral wound healing in rats.CD8+ T cells regulate bone tumor burden independent of osteoclast resorption.Role of NF-κB in the skeletonDual-therapy with αvβ3-targeted Sn2 lipase-labile fumagillin-prodrug nanoparticles and zoledronic acid in the Vx2 rabbit tumor model.Breast cancer cell targeting by prenylation inhibitors elucidated in living animals with a bioluminescence reporter.Zoledronic acid in metastatic osteosarcoma: encouraging progression free survival in four consecutive patientsCancer to bone: a fatal attraction.Emerging therapeutic targets in breast cancer bone metastasis.Anticancer properties of zoledronic acid.The critical role of bisphosphonates to target bone cancer metastasis: an overview.Improved union and bone strength in a mouse model of NF1 pseudarthrosis treated with recombinant human bone morphogenetic protein-2 and zoledronic acid.Combined Use of Zoledronic Acid Augments Ursolic Acid-Induced Apoptosis in Human Osteosarcoma Cells through Enhanced Oxidative Stress and Autophagy.Significance of combination therapy of zoledronic acid and gemcitabine on pancreatic cancer.HTLV-1 viral oncogene HBZ induces osteolytic bone disease in transgenic mice.A mathematical model for describing the metastasis of cancer in bone tissue.
P2860
Q33739204-A43E5F45-34C1-4A67-9E0D-037911FB3129Q33786905-CF4F0F3D-7831-418B-A5E5-6972B539C6B8Q34009853-BD9183ED-3005-42AB-8801-B5C3FB7E7D6CQ34024176-CC3E7E80-75A5-4D56-B818-DD877458A85AQ34234108-39FDAC18-9E74-444C-8614-B0E5E4897F78Q34358196-2ACA8947-971C-4187-9291-969338261165Q34441622-C3F1DF93-6883-474E-A060-5531FFC11ADBQ34613492-4B273D37-2805-4808-95EC-5D9F0C124B73Q34694368-3EBF0529-1824-468C-82E6-2E5C15F6D938Q35112793-494A5E79-946B-42CA-AA25-0E420D9E162BQ35347883-DD84A28C-A444-460C-B0A0-338A63E80030Q36505441-9877F954-5921-4DBF-BB64-98E753E4BC41Q36708774-FE219441-946B-4927-9AE8-DD0CC894CD17Q36846801-0EB8388E-A730-42AA-9D3B-84F1F393CED2Q36884628-6E59EA9D-39F6-414B-A755-83AA5893A81BQ37658767-894EA4AB-A6A8-40D2-9140-122FFA1ED7EAQ37794160-92DEA984-88A5-4C76-8E33-20EE3E9FDFACQ38247428-90BB88B9-EFFC-40BA-B782-DD71869A3E90Q38647026-5D8ABE08-C12A-4ADE-966D-A94519C9ABAEQ38727632-BD0F4FCF-97E4-4145-83F2-5E8C79FEBCE8Q39466674-2C65685A-44E1-4185-BBA4-19B6C8CAE3C8Q42378329-6D47658B-1D15-403E-BB35-5B1B6D7C7B48Q51609969-B76FF6D4-0D40-43E1-8F42-4424A1E43FD8
P2860
The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
The bisphosphonate zoledronic ...... ce with defective osteoclasts.
@en
The bisphosphonate zoledronic ...... ce with defective osteoclasts.
@nl
type
label
The bisphosphonate zoledronic ...... ce with defective osteoclasts.
@en
The bisphosphonate zoledronic ...... ce with defective osteoclasts.
@nl
prefLabel
The bisphosphonate zoledronic ...... ce with defective osteoclasts.
@en
The bisphosphonate zoledronic ...... ce with defective osteoclasts.
@nl
P2093
P2860
P1433
P1476
The bisphosphonate zoledronic ...... ce with defective osteoclasts.
@en
P2093
Angela C Hirbe
Anke J Roelofs
Anthony J Apicelli
David Piwnica-Worms
Desiree H Floyd
Hongju Deng
Julie L Prior
Katherine Weilbaecher
Lisa G Lanigan
Mark C Eagleton
P2860
P304
P356
10.1016/J.BONE.2009.01.010
P577
2009-01-23T00:00:00Z